Boston Scientific (NYSE:BSX) Raised to “Hold” at Barclays

Boston Scientific (NYSE:BSX) was upgraded by analysts at Barclays to a “hold” rating in a report issued on Wednesday, Zacks reports.

A number of other research firms have also commented on BSX. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. UBS Group cut their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Needham & Company LLC reduced their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Finally, Raymond James Financial restated an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-two investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.31.

Boston Scientific Stock Up 1.0%

Shares of NYSE BSX opened at $41.98 on Wednesday. The company has a 50 day simple moving average of $46.64 and a 200 day simple moving average of $50.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific has a 1 year low of $41.38 and a 1 year high of $105.65. The firm has a market cap of $60.83 billion, a PE ratio of 16.99, a price-to-earnings-growth ratio of 1.00 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts forecast that Boston Scientific will post 3.25 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward Ludwig purchased 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently bought and sold shares of the stock. Renaissance Group LLC bought a new stake in Boston Scientific during the fourth quarter worth $28,064,000. Perigon Wealth Management LLC bought a new position in Boston Scientific during the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd lifted its stake in Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after acquiring an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC purchased a new position in Boston Scientific during the 2nd quarter worth $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab boosted its holdings in Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after acquiring an additional 28,961 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific appointed longtime cardiovascular executive Joseph M. Fitzgerald as executive vice president and chief operating officer. Management said the new structure, which organizes operations into three segments, is intended to improve efficiency and support continued growth. Investors may view the move as a potential catalyst for better execution. Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
• Neutral Sentiment: The restructuring is receiving additional coverage because Fitzgerald will oversee the three-segment operating model, including changes affecting the cardiovascular business. The strategy could create longer-term benefits, but investors will need evidence that it improves growth and margins. Why Is Boston Scientific Reorganizing Into Three Segments Under A New COO?
• Neutral Sentiment: Barclays initiated coverage with an “equal weight” rating and later described the shares as “hold.” The rating signals limited near-term conviction rather than a clear bullish or bearish stance. Barclays initiates coverage of Boston Scientific with equal-weight
• Negative Sentiment: BSX reached a new 52-week low during trading, highlighting continued selling pressure and investor concerns despite the announced leadership changes. The stock remains well below its 52-week high, increasing the importance of upcoming execution and earnings results. Boston Scientific Reaches New 1-Year Low
• Negative Sentiment: Citigroup issued a pessimistic forecast for Boston Scientific, adding to the cautious analyst tone around the shares. This offsets some of the potential optimism from the new operating structure. Citigroup Issues Pessimistic Forecast for Boston Scientific

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.